Therapeutics
Search By Attributes
Search Results
| Name | Synonyms | FDA Status | Company | Target Type | Therapy Type | Approved For |
|---|---|---|---|---|---|---|
| AL101 | GSK-4527226 | Alzheimer's Disease (Phase 2) | Alector, GlaxoSmithKline (GSK) | Other | Immunotherapy (passive) | |
| ANX005 | Amyotrophic Lateral Sclerosis (Phase 2) | Annexon, Inc. | Inflammation, Other | Immunotherapy (passive) | ||
| Bepranemab | UCB0107, UCB 0107, Antibody D |
Progressive Supranuclear Palsy (Phase 1), Alzheimer's Disease (Phase 2) | Hoffmann-La Roche, UCB S.A. | Tau | Immunotherapy (passive) | |
| BMS-986446 | PRX005 | Alzheimer's Disease (Phase 2) | Bristol-Myers Squibb, Prothena | Tau | Immunotherapy (passive) | |
| Etanercept | Enbrel™ | Alzheimer's Disease (Phase 2) | Amgen, Inc., Pfizer | Inflammation | Immunotherapy (passive) | Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondilysis |
| Exidavnemab | BAN0805, ABBV-0805 |
Parkinson's Disease (Phase 2), Multiple System Atrophy (Phase 2) | AbbVie, BioArctic AB | alpha-synuclein | Immunotherapy (passive) | |
| Foralumab | TZLS-401, NI-0401, 28F11-AE |
Alzheimer's Disease (Phase 2), Amyotrophic Lateral Sclerosis (Phase 2) | Tiziana Life Sciences | Inflammation | Immunotherapy (passive) | |
| LU AF82422 | Parkinson's Disease (Phase 1), Multiple System Atrophy (Phase 2) | Genmab A/S, Lundbeck | alpha-synuclein | Immunotherapy (passive) | ||
| MK-2214 | Alzheimer's Disease (Phase 2) | Merck | Tau | Immunotherapy (passive) | ||
| Pepinemab | VX15, VX15/2503 |
Alzheimer's Disease (Phase 1/2), Huntington's Disease (Phase 2) | Vaccinex, Inc. | Inflammation | Immunotherapy (passive) | |
| Posdinemab | JNJ-63733657 | Mild AD (Phase 2) | Janssen | Tau | Immunotherapy (passive) | |
| Prasinezumab | PRX002, RO7046015, RG7935, NEOD002 | Parkinson's Disease (Phase 2) | Hoffmann-La Roche, Prothena | alpha-synuclein | Immunotherapy (passive) | |
| SHR-1707 | Alzheimer's Disease (Phase 2) | Amyloid-Related | Immunotherapy (passive) | |||
| TAK-341 | MEDI1341 | Parkinson's Disease (Phase 1), Multiple System Atrophy (Phase 2) | AstraZeneca, Takeda Pharmaceutical Company | alpha-synuclein | Immunotherapy (passive) | |
| VHB937 | Alzheimer's Disease (Phase 1), Amyotrophic Lateral Sclerosis (Phase 2) | Novartis Pharmaceuticals Corporation | Amyloid-Related | Immunotherapy (passive) |